Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Sep;12(9):1829-36. doi: 10.1158/1535-7163.MCT-13-0208. Epub 2013 Jul 16.

PMID:
23861346
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Identification of docetaxel resistance genes in castration-resistant prostate cancer.

Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B.

Mol Cancer Ther. 2012 Feb;11(2):329-39. doi: 10.1158/1535-7163.MCT-11-0289. Epub 2011 Oct 25.

PMID:
22027694
[PubMed - indexed for MEDLINE]
Free Article
3.

Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC.

Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.

PMID:
22996738
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.

Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, Cheon J, Lee SE, Moon du G.

Anticancer Res. 2014 Jul;34(7):3457-68.

PMID:
24982354
[PubMed - indexed for MEDLINE]
5.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.

PMID:
23954373
[PubMed - indexed for MEDLINE]
6.

Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.

Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN.

Cancer Biol Ther. 2011 Jan 15;11(2):204-12. Epub 2011 Jan 15.

PMID:
21057205
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW.

Mol Cancer. 2011 Oct 7;10:126. doi: 10.1186/1476-4598-10-126.

PMID:
21982118
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
[PubMed - indexed for MEDLINE]
9.

miRNA-34a is associated with docetaxel resistance in human breast cancer cells.

Kastl L, Brown I, Schofield AC.

Breast Cancer Res Treat. 2012 Jan;131(2):445-54. doi: 10.1007/s10549-011-1424-3. Epub 2011 Mar 12.

PMID:
21399894
[PubMed - indexed for MEDLINE]
10.

Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.

Lee BY, Hochgräfe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG, Daly RJ.

Mol Cancer Ther. 2014 Jan;13(1):190-201. doi: 10.1158/1535-7163.MCT-13-0225-T. Epub 2013 Nov 5.

PMID:
24194567
[PubMed - indexed for MEDLINE]
11.

The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR.

Biochem Pharmacol. 2013 Feb 15;85(4):514-24. doi: 10.1016/j.bcp.2012.12.006. Epub 2012 Dec 19.

PMID:
23261525
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.

Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S.

Prostate. 2013 Sep;73(12):1336-44. doi: 10.1002/pros.22681. Epub 2013 Jun 14.

PMID:
23775496
[PubMed - indexed for MEDLINE]
13.

Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.

Reed K, Hembruff SL, Laberge ML, Villeneuve DJ, Côté GB, Parissenti AM.

Epigenetics. 2008 Sep;3(5):270-80.

PMID:
19001875
[PubMed - indexed for MEDLINE]
Free Article
14.

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.

Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077.

PMID:
19866475
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure].

Chen BD, Yu SC, Li GH.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Jan;43(1):115-8. Review. Chinese.

PMID:
24616470
[PubMed - indexed for MEDLINE]
16.

Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming.

Kosaka T, Nagamatsu G, Saito S, Oya M, Suda T, Horimoto K.

Cancer Sci. 2013 Aug;104(8):1017-26. doi: 10.1111/cas.12183. Epub 2013 May 26.

PMID:
23600803
[PubMed - indexed for MEDLINE]
17.

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27.

PMID:
21795074
[PubMed - indexed for MEDLINE]
18.

L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.

Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT.

Toxicol Lett. 2010 Feb 15;192(3):408-18. doi: 10.1016/j.toxlet.2009.11.018. Epub 2009 Nov 26.

PMID:
19944135
[PubMed - indexed for MEDLINE]
19.

Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY.

Mol Cancer Ther. 2010 Jun;9(6):1831-41. doi: 10.1158/1535-7163.MCT-09-0880. Epub 2010 May 25.

PMID:
20501799
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.

Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M.

J Urol. 2011 Jun;185(6):2376-81. doi: 10.1016/j.juro.2011.02.016. Epub 2011 Apr 20.

PMID:
21511293
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk